Provenance trace
Audit trail · riluzole → MMP-9 → forced vital capacity
2 source papers, 2 extracted claims, scored by Swanson ABC chain.
Backfilled retroactively from DB state on 2026-05-13. The pipeline_run this row references was created by the backfill script, not by the actual generation orchestrator. Source papers, claims, scoring, and embedding config are recovered; generation-time metadata (exact git commit at gen time, host, exact command) is not recoverable.
1Source papers2
2Extracted claims2
Each row is one structured triple extracted by deepseek-v4-flash (prompt v1_2026_05_07,
source: configured). Confidence is the LLM's self-rating.
- riluzoledownregulatesMMP-9A→B
- MMP-9correlates_withforced vital capacityB→C
No claims match this filter.
3Bridging logicSwanson ABC
- edge_support_log_ab
- log(ab + 1) =
0.693 - edge_support_log_bc
- log(bc + 1) =
0.693 - novelty_factor
1.000(no direct drug→outcome evidence — full novelty)- direct_a_to_c_count
0
4Embedding modelbge-m3
Embeddings are used at the L1 filtering stage to prune off-topic abstracts before claim extraction. They do not directly score the hypothesis.
- model
bge-m3- dim
1024- max_length
8192tokens- similarity_scores
- No per-hypothesis cosine scores stored.
5Final scoringmid · 0.208
- method
swanson_abc_log_evidence_with_novelty_penalty- formula
score = min((log(ab+1) + log(bc+1)) * novelty / 10, 1.0); novelty = 1.0 if direct==0 else 0.7 / (direct+1)- raw score
0.1386- outreach score
0.2079- quality tier
mid
Horizontal exploration
Similar hypotheses
Closest 8 of 1,618 hypotheses, ranked by hybrid score (50% bge-m3 embedding cosine · 40% drug/mediator/outcome overlap · 10% shared evidence papers).
- New indication0.94riluzole→MMP-9→prevalent ILD
Same drug + same mediator, different disease
- New indication0.94riluzole→MMP-9→incident ILD
Same drug + same mediator, different disease
- Cross-indication0.89riluzole→MMP-2→all-cause mortality
Same drug, different disease — potential alternate indication
- Cross-indication0.89riluzole→MMP-2→cardiovascular events
Same drug, different disease — potential alternate indication
- Cross-indication0.89riluzole→MMP-2→albuminuria
Same drug, different disease — potential alternate indication
Show 3 more
- Cross-indication0.89riluzole→MMP-2→retinopathy
Same drug, different disease — potential alternate indication
- Cross-indication0.88riluzole→MMP-2→office pulse pressure
Same drug, different disease — potential alternate indication
- Cross-indication0.88riluzole→MMP-2→brachial 24-h pulse pressure
Same drug, different disease — potential alternate indication
How this hypothesis evolved
First captured May 12, 2026, latest May 13, 2026. 2 snapshots.